This series of phase 3, randomised, double-blind, placebo-controlled clinical trials involved more than 25,000 individuals with overweight or obesity and has extensively demonstrated the efficacy of once-weekly subcutaneous semaglutide 2.4 mg in promoting weight loss [13, 38,39,40,41,42,43,44,45,46]
Once you begin Tirzepatide treatment, we will provide ongoing monitoring and support to ensure the medication is working effectively and to make any necessary adjustments to your treatment plan
For volume or wholesale pricing, click Contact Sales or email [email protected] with any further questions
Khanal, S., Wieland, A
However, the authors of the latter study emphasized the need for further studies to draw more definitive conclusions